SCHEMBL21033946

SCHEMBL21033946

CCOC(=O)c1cn2cc(N3CC(F)(F)C3)ncc2n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.49
POLB P06746 1/20 0.49
GAA P10253 2/20 0.44
RAB9A P51151 5/20 0.44
NPC1 O15118 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.39
SMO Q99835 1/20 0.38
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GABRA2 P47869 3/20 0.37
GABRB2 P47870 3/20 0.37
CNR2 P34972 2/20 0.36
GLA P06280 1/20 0.35
AKT1 P31749 1/20 0.35
AKT2 P31751 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19736938 0.82 PIK3CA (0.51) KDM4EPOLBGAARAB9ANPC1
SCHEMBL21033326 0.82 PTGS1 (0.39) RXFP1CNR2
SCHEMBL21033711 0.81 KDM4E (0.54) KDM4EPOLBGAARAB9ANPC1
SCHEMBL21033290 0.81 KDM4E (0.46) KDM4EPOLBGAARAB9ANPC1
SCHEMBL21033953 0.81
SCHEMBL15176026 0.79 KDM4E (0.62) KDM4EPOLBGAARAB9ANPC1
SCHEMBL20384719 0.75 KDM4E (0.58) KDM4EPOLBGAARAB9ANPC1
SCHEMBL26094448 0.75 KDM4E (0.54) KDM4EPOLBGAARAB9ANPC1
SCHEMBL2730806 0.75 KDM4E (0.54) KDM4EPOLBGAARAB9ANPC1
SCHEMBL23534366 0.74 KDM4E (0.53) KDM4EPOLBGAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704120-B1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC (US) 2024-03-06 EP disclosed
US-11459338-B2 Heterocyclic compounds as PRMT5 inhibitors JUBILANT EPISCRIBE LLC (US) 2022-10-04 US disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 US disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459338-B2 Heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 KDM4E 221/4885POLB 1269/4885GAA 3971/4885
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM4E 221/4885POLB 1269/4885GAA 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.